Skip to main contentAI and Advanced
/
TATVA · NSEMarket ticker unavailable · configure an authorised index feed
TA
NSE · Equity shares · Chemical Manufacturing100.60 · 6.45%
Tatva Chintan Pharma Chem TATVA
NSE:INR 1,659.6
BSE:INR 1,708
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for TATVA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,559
Day rangeINR 1,520 — INR 1,666.6
52-week rangeINR 981.5 — INR 1,838.1
Volume1.09 L
Market cap3,995.36
P/E54.36
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)505.86
Net Income (INR Cr)42.05
Rev Growth (5 Year %)10.99
EPS Growth (5 Year %)-5.28
P/E Ratio54.36
EPS17.98
Research path: Interpret Tatva Chintan Pharma Chem's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
TATVATatva Chintan Pharma Chem1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,003.69 | 836.25 | 818.72 |
| Cash Equivalents | 8.79 | 0.46 | 14.8 |
| Other Liabilities Total | 3.79 | 1.4 | 1.33 |
| Long Term Debt | 5.01 | 0 | Not available |
| Common Stock Total | 23.39 | 23.39 | 23.39 |
| Other Current Assets Total | 23.94 | 3.07 | 3.74 |
| Total Assets | 1,003.69 | 836.25 | 818.72 |
| Current Portof LT Debt/Capital Leases | 115.36 | 0.64 | 3.63 |
| Total Equity | 781.76 | 738.82 | 737.08 |
| Long Term Investments | 8.95 | 0 | Not available |
| Retained Earnings(Accumulated Deficit) | 758.37 | 308.53 | 307.71 |
| Total Common Shares Outstanding | 2.34 | 2.34 | 2.34 |
| Tangible Book Valueper Share Common Eq | 331.28 | 313.32 | 313.41 |
| Total Liabilities | 221.94 | 97.43 | 81.64 |
| Total Debt | 120.37 | 36.39 | 14.27 |
| Short Term Investments | 0.36 | 0.33 | 10.36 |
| Cashand Short Term Investments | 9.15 | 11.7 | 45.67 |
| Total Receivables Net | 120.35 | 108.61 | 88.13 |
| Accounts Receivable-Trade Net | 119.03 | 90.02 | 72.36 |
| Property/Plant/Equipment Total-Net | 627.5 | 547.09 | 499.46 |
| Total Current Liabilities | 213.14 | 96.03 | 79.66 |
| Total Inventory | 196.07 | 133.95 | 152.77 |
| Accounts Payable | 58.25 | 32.69 | 45.03 |
| Other Currentliabilities Total | 39.53 | 16.08 | 13.4 |
| Total Long Term Debt | 5.01 | 0 | 0.64 |
| Intangibles Net | 6.83 | 5.9 | 3.96 |
| Other Long Term Assets Total | 10.91 | 18.02 | 17.39 |
| Total Current Assets | 349.51 | 265.25 | 297.91 |
| Accumulated Depreciation Total | Not available | -86.94 | -60.44 |
| Accrued Expenses | Not available | 10.87 | 7.6 |
| Other Equity Total | Not available | 2.51 | 1.58 |
| Prepaid Expenses | Not available | 7.91 | 7.61 |
| Additional Paid-In Capital | Not available | 404.39 | 404.39 |
| Cash | Not available | 10.92 | 20.51 |
| Property/Plant/Equipment Total-Gross | Not available | 612.5 | 486.98 |
| Notes Payable/Short Term Debt | Not available | 35.75 | 10 |
| Capital Lease Obligations | Not available | 0 | 0.64 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %5.93
Margins
Operating Margin 12m12.29
Operating Margin 5y Avg12.4
Net Profit Margin 12m9.24
Net Profit Margin 5y10.26
Yield
Dividend Yield %0.12
Valuation
Price to Sale Ratio7.90
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk50.43
Analyst consensus
ConsensusHold
Consensus score2.80
Analyst opinions5
Strong Sell count1
Sell count1
Hold count1
Buy count0
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,749 | 2.64 L | 58.09 | — |
| Solar Industries India | INR 18,560 | 1.68 L | 99.61 | — |
| Pidilite Industries | INR 1,671 | 1.70 L | 64.76 | — |
| SRF | INR 2,626 | 77,841.16 | 44.57 | — |
| Linde India | INR 7,105 | 61,033.66 | 110.53 | — |
Shareholding
Ownership
- Promoter
- 72.02%
- FII
- 3.93%
- MF
- 2.79%
- Other
- 21.26%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Tatva Chintan Q1 net profit rises 54.8% to ₹159.81 million - scanx.tradeMarket news · 21 Jul 2026, 3:29 pm
Tatva Chintan Q1 net profit rises 54.8% to ₹159.81 million scanx.trade
Tatva Chintan Pharma Chem Expands Manufacturing Footprint with New Dahej-III Greenfield Unit. - News on ProjectsMarket news · 21 Jul 2026, 2:28 pm
Tatva Chintan Pharma Chem Expands Manufacturing Footprint with New Dahej-III Greenfield Unit. News on Projects
Broad-Based Technical Strength Lifts Tatva Chintan Pharma Chem Ltd to 52-Week High of Rs 1786.7 - MarketsMojoMarket news · 21 Jul 2026, 10:06 am
Broad-Based Technical Strength Lifts Tatva Chintan Pharma Chem Ltd to 52-Week High of Rs 1786.7 MarketsMojo
Tatva Chintan Pharma Chem Ltd conducts Bhoomi Pujan for new greenfield unit at Dahej - III - EquityBullsMarket news · 20 Jul 2026, 9:05 pm
Tatva Chintan Pharma Chem Ltd conducts Bhoomi Pujan for new greenfield unit at Dahej - III EquityBulls
Tatva chintan pharma chem sets sights on 200 crore greenfield expansion to meet surging demand - IndiatimesMarket news · 20 Jul 2026, 4:44 pm
Tatva chintan pharma chem sets sights on 200 crore greenfield expansion to meet surging demand Indiatimes
8 Stocks That Hit the 20% Upper Circuit Today; Do You Own Any? - Trade BrainsMarket news · 20 Jul 2026, 3:29 pm
8 Stocks That Hit the 20% Upper Circuit Today; Do You Own Any? Trade Brains
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(20%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.0000 per share(10%)Final Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Tatva Chintan Pharma Chem
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Tatva Chintan Pharma Chem Limited is an India-based specialty chemical manufacturing company. The Company is primarily engaged in manufacturing, sale and distribution of specialty chemicals, phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). It operates in the Specialty chemical segment. Its SDA is a high purity quaternary salt, which plays a role in forming channels during the synthesis of zeolites. PTC acts as a catalyst in chemical reactions, facilitating reactions between reactants of different phases. Its products serve various sectors, including automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances. The Company operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India.
Company facts
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- NSE Code
- TATVA
- BSE Code
- 543321
Questions
Stock FAQ
What is the symbol and ISIN of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has the symbol TATVA and ISIN - INE0GK401011.
What is the current price of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem is currently trading at INR 1,659.60.
What are the year high and year low of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a year high of INR 1,838.10 and a year low of INR 981.50.
What is the market capitalization of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a market capitalization of INR 3,995.36 crore.
What is the P/E ratio of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a P/E ratio of 54.36.
What is the dividend yield of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a dividend yield of 0.12%.
How is the financial performance of Tatva Chintan Pharma Chem based on revenue, net income, and EPS?
Tatva Chintan Pharma Chem has revenue of INR 505.86 crore, net income of INR 42.05 crore, and EPS of INR 22.40.
What is the book value of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a book value of NA.
What is the debt-to-equity ratio of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a price-to-book ratio of NA and a price-to-sales ratio of 7.90.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.